FindTrial
Sign In

SCH900475

3 trials

Sponsors

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Conditions

Non-Small Cell Lung CarcinomaRecurrent or Metastatic Head and Neck Squamous Cell Carcinoma MedDRA version: 19.1 Level: PT Classification code 10067821 Term: Head and neck cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)advanced/unresectable (inoperable) or metastatic urothelial cancer of the renal pelvis, ureter, bladder, or urethra. MedDRA version: 17.1 Level: LLT Classification code 10046714 Term: Urothelial carcinoma bladder System Organ Class: 100000004864

Phase 2

A Phase II Trial of MK-3475 in Subjects with Bladder Cancer
Active, not recruitingEUCTR2014-002206-20-ES
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.advanced/unresectable (inoperable) or metastatic urothelial cancer of the renal pelvis, ureter, bladder, or urethra. MedDRA version: 17.1 Level: LLT Classification code 10046714 Term: Urothelial carcinoma bladder System Organ Class: 100000004864
Start: 2014-12-22Target: 350Updated: 2022-05-09

Phase 3

OS Study of Pembrolizumab (MK-3475) vs. SOC in Treatment Naïve Subjects with PD-L1 Positive Advanced or Metastatic NSCLC (Keynote 042)
Active, not recruitingEUCTR2014-001473-14-SE
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.Non-Small Cell Lung Carcinoma
Start: 2014-10-14Target: 1250Updated: 2021-10-08
Ph 3 Trial of MK-3475 (Pembrolizumab) vs Standard Treatment in Recurrent/Metastatic Head and Neck Cancer
Active, not recruitingEUCTR2014-001749-26-IE
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma MedDRA version: 19.1 Level: PT Classification code 10067821 Term: Head and neck cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Start: 2014-11-21Target: 466Updated: 2017-02-13